Biodesix Presents Data Showing Veristrat Useful for Identifying Avastin-Tarceva Responders | GenomeWeb

Biodesix last week presented results from a combined analysis of two Phase II trials using its Veristrat lung cancer companion diagnostic.

The results, which were shared at the Third European Lung Cancer Conference in Geneva, demonstrated that Veristrat was able to identify non-squamous non-small cell lung cancer patients likely to have better and worse survival outcomes when given combination therapy of bevacizumab – marketed by Roche as Avastin – and erlotinib – marketed by Roche as Tarceva.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."